Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection
-
Published:2008-10
Issue:10
Volume:52
Page:3617-3632
-
ISSN:0066-4804
-
Container-title:Antimicrobial Agents and Chemotherapy
-
language:en
-
Short-container-title:Antimicrob Agents Chemother
Author:
Menne Stephan1, Butler Scott D.1, George Andrea L.1, Tochkov Ilia A.1, Zhu Yuao2, Xiong Shelly2, Gerin John L.3, Cote Paul J.3, Tennant Bud C.1
Affiliation:
1. Gastrointestinal Unit, Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853 2. Gilead Sciences, Inc., 4 University Place, 4611 University Drive, Durham, North Carolina 27707 3. Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC 20057
Abstract
ABSTRACT
Adefovir dipivoxil (ADV) and tenofovir disoproxil fumarate (TDF) are nucleotide analogs that inhibit the replication of wild-type hepatitis B virus (HBV) and lamivudine (3TC)-resistant virus in HBV-infected patients, including those who are coinfected with human immunodeficiency virus. The combination of ADV or TDF with other nucleoside analogs is a proposed strategy for managing antiviral drug resistance during the treatment of chronic HBV infection. The antiviral effect of oral ADV or TDF, alone or in combination with 3TC or emtricitabine (FTC), against chronic woodchuck hepatitis virus (WHV) infection was evaluated in a placebo-controlled study in the woodchuck, an established and predictive model for antiviral therapy. Once-daily treatment for 48 weeks with ADV plus 3TC or TDF plus FTC significantly reduced serum WHV viremia levels from the pretreatment level by 6.2 log
10
and 6.1 log
10
genome equivalents/ml serum, respectively, followed by TDF plus 3TC (5.6 log
10
genome equivalents/ml), ADV alone (4.8 log
10
genome equivalents/ml), ADV plus FTC (one survivor) (4.4 log
10
genome equivalents/ml), TDF alone (2.9 log
10
genome equivalents/ml), 3TC alone (2.7 log
10
genome equivalents/ml), and FTC alone (2.0 log
10
genome equivalents/ml). Individual woodchucks across all treatment groups also demonstrated pronounced declines in serum WHV surface antigen, characteristically accompanied by declines in hepatic WHV replication and the hepatic expression of WHV antigens. Most woodchucks had prompt recrudescence of WHV replication after drug withdrawal, but individual woodchucks across treatment groups had sustained effects. No signs of toxicity were observed for any of the drugs or drug combinations administered. In conclusion, the oral administration of 3TC, FTC, ADV, and TDF alone and in combination was safe and effective in the woodchuck model of HBV infection.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference71 articles.
1. Akyildiz, M., F. Gunsar, G. Ersoz, Z. Karasu, T. Ilter, Y. Batur, and U. Akarca. 2007. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig. Dis. Sci.52:3444-3447. 2. Angus, P., R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology125:292-297. 3. Benhamou, Y., M. Bochet, V. Thibault, V. Calvez, M. H. Fievet, P. Vig, C. S. Gibbs, C. Brosgart, J. Fry, H. Namini, C. Katlama, and T. Poynard. 2001. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet358:718-723. 4. Benhamou, Y., V. Thibault, P. Vig, V. Calvez, A. G. Marcelin, M. H. Fievet, G. Currie, C. G. Chang, L. Biao, S. Xiong, C. Brosgart, and T. Poynard. 2006. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J. Hepatol.44:62-67. 5. Benhamou, Y., R. Tubiana, and V. Thibault. 2003. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N. Engl. J. Med.348:177-178.
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|